Journal of Cellular Biochemistry

Recent advances in proteomic technologies applied to cardiovascular disease

Authors

  • Claudio Napoli,

    Corresponding author
    1. Department of General Pathology, Excellence Research Centre on Cardiovascular Disease, U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], Azienda Ospedaliera Universitaria (AOU), 1st School of Medicine, Second University of Naples, 80138 Naples, Italy
    2. Fondazione Studio Diagnostica Nucleare (SDN), IRCCS, 80100 Naples, Italy
    • U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], Azienda Ospedaliera Universitaria (AOU), 1st School of Medicine, Second University of Naples, Via Costantinopoli, 16—80138, Naples, Italy.
    Search for more papers by this author
  • Alberto Zullo,

    1. Department of Science for Biology, Geology and Environment, University of Sannio, 82100 Benevento, Italy
    2. CEINGE Biotecnologie Avanzate s.c.a r.l., 80145 Naples, Italy
    Search for more papers by this author
  • Antonietta Picascia,

    1. Department of General Pathology, Excellence Research Centre on Cardiovascular Disease, U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], Azienda Ospedaliera Universitaria (AOU), 1st School of Medicine, Second University of Naples, 80138 Naples, Italy
    Search for more papers by this author
  • Teresa Infante,

    1. Fondazione Studio Diagnostica Nucleare (SDN), IRCCS, 80100 Naples, Italy
    Search for more papers by this author
  • Francesco Paolo Mancini

    1. Department of Science for Biology, Geology and Environment, University of Sannio, 82100 Benevento, Italy
    2. Department of Biochemistry and Medical Biotechnology, University of Naples, “Federico II”, 80131 Naples, Italy
    Search for more papers by this author

Abstract

In recent years, the diagnosis of cardiovascular disease (CVD) has increased its potential, also thanks to mass spectrometry (MS) proteomics. Modern MS proteomics tools permit analyzing a variety of biological samples, ranging from single cells to tissues and body fluids, like plasma and urine. This approach enhances the search for informative biomarkers in biological samples from apparently healthy individuals or patients, thus allowing an earlier and more precise diagnosis and a deeper comprehension of pathogenesis, development and outcome of CVD to further reduce the enormous burden of this disease on public health. In fact, many differences in protein expression between CVD-affected and healthy subjects have been detected, but only a few of them have been useful to establish clinical biomarkers because they did not pass the verification and validation tests. For a concrete clinical support of MS proteomics to CVD, it is, therefore, necessary to: ameliorate the resolution, sensitivity, specificity, throughput, precision, and accuracy of MS platform components; standardize procedures for sample collection, preparation, and analysis; lower the costs of the analyses; reduce the time of biomarker verification and validation. At the same time, it will be fundamental, for the future perspectives of proteomics in clinical trials, to define the normal protein maps and the global patterns of normal protein levels, as well as those specific for the different expressions of CVD. J. Cell. Biochem. 114: 7–20, 2012. © 2012 Wiley Periodicals, Inc.

Ancillary